So weve put together the facts about each treatment, including their longevity, ideal candidates, and what the procedures entail
Per-plan formulary tier specifics are not publicly published
range 6293) and 3.0 mg (777 beats per min
Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss Eli Lilly, "Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials" (July 23, 2026) TRIUMPH-2 (20.8% at 12 mg, A1C up to -1.6%) and TRIUMPH-3 (22.6% at 12 mg) topline, plus the stated plan to submit a BLA to the FDA in Q1 2027 ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al
Its thought that sodium lauryl sulfate, a common ingredient in toothpastes, could also trigger canker sores, so it might be a good idea to find a toothpaste without it if you have recurrent sores, and also discuss it with your dentist
You prioritize long-term safety data
